Ochre Bio company information, Employees & Contact Information

Biotech Start-Up Ochre Bio Relocates to Alexandria Center for Life Science – New York City citybiz

After building Ochre Bio, Jack O’Meara’s newest biotech raises $21M for neuro siRNAs Endpoints News

Liver Disease Researcher Ochre Bio Signs 6K-SF Lease at Biotech Center Commercial Observer

Dr Quin Wills Appointed as Ochre Bio CEO Health Tech World

Ochre Bio, addressing the complexities of liver disease Maddyness

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment Citeline News & Insights

Ochre Bio appoints Elaine Sullivan as senior independent non-executive director Pharmafile

GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease Business Wire

RNA Therapies in Liver Disease: Insights from Ochre Bio's CEO News-Medical

Wilson Sonsini Advises Ochre Bio on $37.5 Million License Agreement with GSK to Investigate Liver Disease Wilson Sonsini

Boehringer, Ochre Bio Team in Potential $1B Deal to Develop Regenerative Liver Drugs BioSpace

Exploring liver disease therapies Drug Target Review

Boehringer Ingelheim, Ochre Bio Launch Up-to-$1B+ Liver Disease Partnership Genetic Engineering and Biotechnology News

GSK signs AI pact with Ochre to pinpoint source of liver diseases Fierce Biotech

RNA therapies startup Ochre Bio lands $30M to take on chronic liver disease MedCity News

Ochre Bio CEO Jack O’Meara steps down, outlines plans for next startup Endpoints News

Ochre Bio Raises $30M Series A Financing for the Development of RNA Therapies for Chronic Liver Diseases Business Wire

Boehringer signs $1.3B deal with RNA biotech Ochre Bio to team up against MASH Fierce Biotech

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors Business Wire

Ochre Bio Announces Formation of Scientific Strategy Board with Liver Disease Experts Business Wire

Ochre Bio and Boehringer enter CLD regenerative therapy deal Pharmaceutical Technology

Boehringer Ingelheim and Ochre Bio partner on liver disease in deal worth over $1bn PharmaTimes

Boehringer Ingelheim teams with Ochre Bio on $1.3B deal to combat MASH Medical Marketing and Media

UK biotech signs $1bn deal to develop liver disease drugs Financial Times

The Pharma Letter Podcast — Episode 33 — Why Boehringer and GSK are betting on Ochre The Pharma Letter

GSK and Ochre Bio enter multi-year partnership to investigate liver disease drivers PMLiVE

Biotech Startup Ochre Bio Lands Seed Financing to Combat Liver Diseases The Wall Street Journal

GSK taps into Ochre's data vault to decode liver disease drivers FirstWord Pharma

Irish-founded Ochre Bio raises $30m to develop liver disease treatments Silicon Republic

The intersection between healthcare, technology, strategy and impact - Interview with Ochre Bio's CEO and co-founder Jack O’Meara EU-Startups

Irish-founded Ochre Bio teams up with GSK to tackle liver disease Silicon Republic

This company aims to end the need for liver transplants — as thousands die every year on the waitlist New York Post

Derisking clinical trials requires a ‘human first’ approach Longevity.Technology

Boehringer Ingelheim Strikes Regenerative Med R&D Deal Spanning MASH & More Liver Diseases MedCity News

Irish-founded Ochre Bio raises $30m in Series A funding round The Irish Times

How Ochre Bio landed a deal worth up to $1.3bn with a German pharma giant The Currency

Aerska Launches with $21 Million in Financing to Develop RNAi Medicines for Diseases of the Brain BioSpace

GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets Fierce Biotech

Seven Lessons I Learned Working at a Biotech Startup Pharmaceutical Executive

Oxford’s Ochre Bio signs billion-dollar deal to develop liver disease drugs Insider Media Ltd

Irish co-founded Ochre Bio signs $1.3bn deal with German drugmaker Business Post

Irish co-founded Ochre Bio signs $37.5m deal with pharma giant GSK Business Post

Unravelling the most complex disease challenges in history: how AI startups are changing drug discovery Startups Magazine

13 techbio startups to watch, according to investors Sifted

Mount Temple man steps back from biotech firm Westmeath Independent

Dublin biotech Aerska raises €18m to pioneer RNA medicines for Alzheimer’s and Parkinson’s Business Post

18 European techbio startups to watch — according to investors Sifted

Irishman’s UK biotech startup backed by billionaire The Irish Independent

Forbes 30 under 30: Six Irish business people make prestigious list for 2023 The Irish Independent